Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib + osimertinib versus pemetrexed + platinum in EGFR TKI-failed MET-amplified advanced non-small cell lung cancer
CTR20211441Phase 3Completed
- Sponsor
- HUTCHMED
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of savolitinib, osimertinib in non-small cell lung cancer (NSCLC), sponsored by HUTCHMED. Started Nov 2021; status: completed.
02
Drugs
savolitinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211441.